• A
• B
• C
• D
• E
• F
• G
• H
• I
• K
• L
• M
• N
• O
• P
• R
• S
• T
• U
• V
• Z

Pembrolizumab (Keytruda®) for head and neck squamous cell carcinoma. HTA ID: 19051

Pembrolizumab (Keytruda®) for metastatic triple negative breast cancer. HTA ID: 21059

Pembrolizumab (Keytruda®) for NSCLC (first line)

Pembrolizumab (Keytruda®) for NSCLC (second line)

Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma . HTA ID: 21032

Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.

Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.

Pembrolizumab (Keytruda®) in combination with axitinib (Inlyta®) for 1L RCC. HTA ID: 19027

Pentosan Polysulfate Sodium [PPS] (Elmiron®)

Perampanel (Fycompa®)